Cancer Institute

  • Ingrid Espinoza

    Espinoza Ingrid.2.jpgAssistant Professor, Department of Preventive Medicine
    Tumor Cell Biology Program
    PhD, Biomedical Sciences, 2002, University of Chile, Santiago, Chile
    Postdoctoral fellow, 2002-04, University of Chile, Santiago, Chile
    Postdoctoral fellow, 2004-08, Northwestern University, Evanston, IL
    Professional Associate in Research, 2008-11, Mayo Clinic, Rochester, MN

    Contact information
    2500 N State St, Room G761
    Jackson, MS 39216
    Phone: (601) 815-3511

    Research interests

    • Identification of molecular biomarkers involved in drug resistance in tumors including colorectal, prostate and breast
    • Development of combinatorial-targeted therapies for breast cancer

    Research synopsis and clinical work

    Dr. Espinoza is a PhD in Biomedical Sciences and a Clinical Research Certified investigator with expertise in cancer. At UMMC, she has been performing as a translational and clinical cancer investigator and as a clinical operations manager. In these roles, Dr. Espinoza has been responsible for overall management of the development of clinical studies, establishing a collaborative link between basic and clinical researchers in different research areas. Currently, she is a co-investigator in several studies related to cancer, cardiovascular diseases and pharmacology. Her roles on these studies include:

    • Coordinate interdisciplinary activities, lead protocol execution team(s), set goals and establish timelines.
    • Preparation and IRB submission of clinical study protocols, informed consent forms, clinical study reports and other clinical documents as necessary. 
    • Ensure development and execution of activities proposed in the study protocols, including data collection and management using REDCap.
    •  Manage all aspects of study progress to assure adherence to planned timelines and achievement of study goals.

    In the research area, Dr. Espinoza is focused on the identification of molecular biomarkers involved in drug resistance in tumors including colorectal, prostate and breast, as a way to develop new combinatorial and targeted therapies for cancer patients to improve cancer patients' survival and well-being.

    Recent accomplishments and honors

    • 2007 - AACR-WICR Brigid G. Leventhal Scholar Award in Cancer Research, Los Angeles, CA.
    • 2008 - Young Investigator Award. Mayo Clinic Angiogenesis Symposium. Rochester, MN,
    • 2008 - Susan G. Komen for the Cure-AACR Minority Scholar Award. San Antonio, TX
    • 2010 - Mayo Clinic Young Investigator Research Symposium. Rochester, MN, U.S.A. Finalist.
    • 2016 - Coauthor of the publication selected to feature Issue 117 of JCB. Cover Image, Volume 117, Number 6, June 2016.

    Selected publications

    • p53 Modulates Notch Signaling in MCF-7 Breast Cancer Cells by Associating with the Notch Transcriptional Complex via MAML1. J Cell Physiol.  Yun J, Espinoza I, Pannuti A, Romero D, Martinez L, Caskey M, Stanculescu A, Bocchetta M, Rizzo P, Band V, Band H, Kim HM, Park SK, Kang KW, Avantaggiati ML, Gomez CR, Golde T, Osborne B, Miele L. J. Cell Physiol. 2015 May 29. doi: 10.1002/jcp.25052. [Epub ahead of print]
    • Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling. Menendez JA, Schroeder B, Peirce SK, Vellon L, Papadimitropoulou A, Espinoza I, Lupu R. J Natl Cancer Inst. 2015 Apr 16;107(6):djv090. doi: 10.1093/jnci/djv090. Print 2015 Jun.
    • CCN1 promotes vascular endothelial growth factor secretion through αvβ 3 integrin receptors in breast cancer. Espinoza I, Menendez JA, Kvp CM, Lupu R.  J Cell Commun Signal. 2014 Mar;8(1):23-7. doi: 10.1007/s12079-013-0214-6. Epub 2013 Dec 12.
    • Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Onco Targets Ther. 2013 Sep 6;6:1249-1259. Review. PMID:24043949[PubMed - as supplied by publisher] Free PMC
    •  Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells, Espinoza I, Miele L. Cancer Lett. 2013 Nov 28;341(1):41-5. doi: 10.1016/j.canlet.2013.08.027. Epub 2013 Aug 21. Review. PMID:23973264[PubMed - indexed for MEDLINE]  
    •  Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, Wu J, Strack PR, Tonetti DA, Miele L. Oncogenesis. 2013 Aug 5;2:e60. doi: 10.1038/oncsis.2013.26. PMID:23917222[PubMed] Free PMC Article 
    • Notch inhibitors for cancer treatment. Espinoza, I. and Miele, L. Pharmacology & Therapeutics,  Aug;139(2):95-110. doi: 10.1016/j.pharmthera.2013.02.003. Epub 2013 Feb 28.PMID:23458608
    • Development of Notch Pathway Inhibitors for Cancer Therapy. Espinoza, I. and Miele, L. Breast Cancer Metastasis and Drug Resistance. Progress and Prospects. Springer. Editor: Aamir Ahmad. 17: 291-327, 2013.
    • CCN1 a Candidate Target for Zoledronic Acid Treatment in Breast Cancer. Espinoza I et al. Mol Cancer Ther. 10:732-41, 2011.
    • Mesocestoides corti: morphological features and glycogen mobilization during in vitro differentiation from larva to adult worm. Cabrera G et al. Parasitology 137:373-84, 2010